MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$651,000K
Net Income
$371,400K
Net Profit Margin
57.05%
EPS
$13.85
Unit: Thousand (K) dollars
Revenue Breakdown
Clinical Diagnostics
Life Science
Revenue Breakdown
US
Europe
Asia Pacific
Americas
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net sales
651,000
592,100
494,600*
653,000
Cost of goods sold
305,200
282,700
314,500*
309,600
Gross profit
345,800
309,400
180,100*
343,400
Selling, general and administrative expense
212,000
212,400
223,900*
206,800
Research and development expense
61,200
62,900
61,700*
71,300
Impairment of purchased intangibles and related items, net
-
-
43,200*
-
Segment profit (gain)
72,600
34,100
-148,700*
65,300
Interest expense
12,100
12,300
12,100*
12,300
Foreign exchange (losss) gaines, net
200
2,400
-2,100*
2,900
(gains) losses from change in fair market value of equity securities and loan receivable
-
-
2,386,300*
-
Marketable securities, unrealized (gain) loss
458,000
-738,200
-
-495,300
Other nonoperating income (expense)
23,400
24,200
65,400*
8,300
Income (loss) from continuing operations before income taxes, noncontrolling interest
542,100
-689,800
2,288,800*
-431,100
(provision) benefit for income taxes
170,700
-162,700
503,200*
-89,200
Net income attributable to bio-rad
371,400
-527,100
1,785,600
-341,900
Basic EPS
13.89
-19.55
64.689
-12.7
Diluted EPS
13.85
-19.55
64.604
-12.7
Basic Average Shares
26,746,000
26,958,000
27,603,000
26,923,000
Diluted Average Shares
26,814,000
26,958,000
27,639,000
26,923,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
BIO-B Income Statement Sankey Diagram
Sankey diagram visualizing BIO-B income statement for the period
Clinical Diagnostics
$399,000K
Life Science
$252,000K
Net sales
$651,000K
Gross profit
$345,800K
Cost of goods sold
$305,200K
Marketable securities,
unrealized (gain) loss
$458,000K
Segment profit (gain)
$72,600K
Other nonoperating
income (expense)
$23,400K
Selling, general and
administrative expense
$212,000K
Research and development
expense
$61,200K
Foreign exchange
(losss) gaines, net
$200K
Income (loss) from
continuing operations...
$542,100K
Interest expense
$12,100K
Net income
attributable to bio-rad
$371,400K
(provision) benefit for
income taxes
$170,700K
Buy us a coffee
BIO-RAD LABORATORIES, INC. (BIO-B)
BIO-RAD LABORATORIES, INC. (BIO-B)